Rock Inhibitors: Future of Anti-glaucoma Medication

Glaucoma constitutes the major burden of irreversible blindness worldwide as of today. All the modalities of treatment are focussed on lowering intraocular pressure (IOP), from medical to surgical. With the advent of new drugs, drug compliance has increased among the patients but still is the most worrisome problem for doctors. Current research is focussed to treat glaucoma by means other than just lowering IOP. Among the various molecules under trial, one group is Rho kinaseinhibitors (ROCK INHIBITORS). They modulate cellular motility of the trabecular meshwork, schlemm’s canal, and ciliary muscle, thereby enhancing aqueous drainage. Being still under trials, hopes are on that these could revolutionise glaucoma therapy.